On 11 Dec 2023, the updated clinical results of Axatilimab at 3 different doses in patients with Chronic Graft-Versus-Host Disease (AGAVE-201) will be reported in 2023 ASH.

Q32 Bio, a biotech company in clinical phase, is regaining full rights for bempikibart (formerly ADX-914) from Amgen to focus on developing immune-balancing biologic therapies.

The application of DPP-4 inhibitors brings new hope to the treatment of Type 2 Diabetes.

argenx reveals green light from European Commission for the subcutaneous usage of VYVGART® (efgartigimod alfa) in treating Generalized Myasthenia Gravis.

The development of dihydrofolate reductase inhibitors has always been challenging. dihydrofolate reductase inhibitors have therapeutic applications in cancer, malaria, and protozoan infections.

The latest clinical findings of KT-333 will be unveiled at the 2023 ASH Congress, setting the stage for subsequent investigations.

DHODH inhibitors are drugs inhibiting the enzyme DHODH crucial in DNA and RNA production, disrupting cell growth.

The first patient was treated with ALE.C04 in a Phase 1/2 study by Alentis Therapeutics, aimed at treating Head and Neck Squamous Cell Carcinoma (HNSCC).

EZH2 inhibition impacts both tumor cells and TME Gaining a deeper understanding of the multiple effects of EZH2i in these patients could potentially aid in predicting clinical responses.

CRISPR Therapeutics and Vertex received approval from the UK's MHRA for the initial gene-edited treatment, CASGEVY™ (exagamglogene autotemcel), targeting Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia employing CRISPR/Cas9 technology.

The 2023 SITC Congress reported that TILT-123, a T-cell inducing oncolytic virus, is safe, effective at fighting tumors, and can boost immune responses in patients with advanced solid tumors.

Carmot Therapeutics has initiated a phase 2 clinical study on CT-868, a unique dual GLP-1/GIP receptor agonist, to treat Type 1 Diabetes.